Compare IIPR & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IIPR | GENB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | IIPR | GENB |
|---|---|---|
| Price | $53.70 | $12.31 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | 294.0K | ★ 810.1K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 14.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.58 | $11.00 |
| 52 Week High | $66.34 | $13.95 |
| Indicator | IIPR | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 57.86 | 48.72 |
| Support Level | $51.47 | $11.00 |
| Resistance Level | $54.14 | $13.70 |
| Average True Range (ATR) | 1.76 | 1.17 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 46.44 | 42.54 |
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.